A. V. Fateeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. V. Fateeva has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Ruslan Aleksandrovich Zukov
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
4 shared publications - Alexey A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Sergei A. Tjulandin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - V. V. Karaseva
N.I. Pirogov Russian National Research Medical University
3 shared publications - A. Z. Isyangulova
Prof. M. Z. Sigal Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Tatarstan
2 shared publications - A.A. Plykina
Russian Society of Clinical Oncology
2 shared publications
Latest Publications
- 28 January 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 3 (3)
А clinical case of etoposide intrathecal administration in a patient with leptomeningial metastasis of nonsmall cell lung cancer
Leptomeningial metastasis of non-small cell lung cancer is a rare and complex clinical case. The lack of randomized clinical trials complicates the process of choosing appropriate treatment methods with the proven efficacy for this cohort of patients and often puts clinicians in a difficult position. Therefore, the search for possible potentially effective treatment options for patients with leptomeningeal metastases is an important direction. Here is a description of a clinical case of a patient with squamous cell lung cancer treatment using intrathecal chemotherapy with etoposide.
- 28 January 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 3 (3)
А clinical case of etoposide intrathecal administration in a patient with leptomeningial metastasis of nonsmall cell lung cancer
Leptomeningial metastasis of non-small cell lung cancer is a rare and complex clinical case. The lack of randomized clinical trials complicates the process of choosing appropriate treatment methods with the proven efficacy for this cohort of patients and often puts clinicians in a difficult position. Therefore, the search for possible potentially effective treatment options for patients with leptomeningeal metastases is an important direction. Here is a description of a clinical case of a patient with squamous cell lung cancer treatment using intrathecal chemotherapy with etoposide.
- Open Access
- 1 November 2025
- Published by Publishing House OKI in Real-World Data & Evidence
- Vol. 5 (3) , 38-46
Pharmacodynamic approach to assessing leukopenia as a marker of treatment efficacy in CDK4/6 inhibitor therapy in patients with HR+/HER2- metastatic breast cancer: a multicenter real-world study
Relevance . The introduction of CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) into clinical practice has significantly improved the treatment outcomes of patients with metastatic HR+/HER2-breast cancer. However, the lack of reliable predictors of therapy response limits the possibilities of personalization of treatment. Leukopenia, the most common hematological complication of CDK4/6 inhibitor therapy, not only reflects the degree of myelosuppression but also serves as an indirect indicator of the pharmacodynamic effect associated with the suppression of bone marrow cell proliferation through a mechanism similar to the targeted effect on the tumor. Despite individual studies demonstrating a potential link between leukopenia degree and therapy effectiveness, data from actual clinical practice remain contradictory and insufficiently systematized. Objective . This study retrospectively examined the possible predictors of CDk4/6 inhibitor effectiveness in clinical practice. Materials and methods. A retrospective, multicenter analysis of data from 170 HR+/HER2-breast cancer patients treated with CDK4/6 inhibitors (palbociclib or ribociclib) in five cancer centers in Siberia and the Far East from 2019 to 2020 was conducted. The patients were stratified into two groups based on the maximum degree of toxicity according to CTCAE v5.0: group 1 (leukopenia G0–1, n=81) and group 2 (leukopenia G≥2, n=89). The primary and secondary endpoints were overall survival (S) and progression-free survival (PFS). Results . Patients in group 2 (leukopenia G≥2) showed a statistically significant increase in median OS compared with group 1 (leukopenia G0-1): 60.0 months (95 % CI: 32.0–72.0) versus 42.0 months (95 % CI: 30.0–60.0), respectively (risk ratio [HR] 0.64; 95 % CI: 0.42–0.97; p=0.034). In the analysis of progression-free survival (PFS), an improvement trend was observed in group 2 (median 68.0 vs 60.0 months), but it did not reach statistical significance (p >0.05). Conclusion . In a real-world study, the development of grade 2 and higher leukopenia during CDK4/6 inhibitor therapy was associated with improved OS. These data confirm that the degree of myelosuppression can serve as a valuable and readily available predictive biomarker of treatment effectiveness.
- 1 November 2025
- Published by Publishing House OKI in Real-World Data & Evidence
- Vol. 5 (3) , 38-46
Open AccessPharmacodynamic approach to assessing leukopenia as a marker of treatment efficacy in CDK4/6 inhibitor therapy in patients with HR+/HER2- metastatic breast cancer: a multicenter real-world study
Relevance . The introduction of CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) into clinical practice has significantly improved the treatment outcomes of patients with metastatic HR+/HER2-breast cancer. However, the lack of reliable predictors of therapy response limits the possibilities of personalization of treatment. Leukopenia, the most common hematological complication of CDK4/6 inhibitor therapy, not only reflects the degree of myelosuppression but also serves as an indirect indicator of the pharmacodynamic effect associated with the suppression of bone marrow cell proliferation through a mechanism similar to the targeted effect on the tumor. Despite individual studies demonstrating a potential link between leukopenia degree and therapy effectiveness, data from actual clinical practice remain contradictory and insufficiently systematized. Objective . This study retrospectively examined the possible predictors of CDk4/6 inhibitor effectiveness in clinical practice. Materials and methods. A retrospective, multicenter analysis of data from 170 HR+/HER2-breast cancer patients treated with CDK4/6 inhibitors (palbociclib or ribociclib) in five cancer centers in Siberia and the Far East from 2019 to 2020 was conducted. The patients were stratified into two groups based on the maximum degree of toxicity according to CTCAE v5.0: group 1 (leukopenia G0–1, n=81) and group 2 (leukopenia G≥2, n=89). The primary and secondary endpoints were overall survival (S) and progression-free survival (PFS). Results . Patients in group 2 (leukopenia G≥2) showed a statistically significant increase in median OS compared with group 1 (leukopenia G0-1): 60.0 months (95 % CI: 32.0–72.0) versus 42.0 months (95 % CI: 30.0–60.0), respectively (risk ratio [HR] 0.64; 95 % CI: 0.42–0.97; p=0.034). In the analysis of progression-free survival (PFS), an improvement trend was observed in group 2 (median 68.0 vs 60.0 months), but it did not reach statistical significance (p >0.05). Conclusion . In a real-world study, the development of grade 2 and higher leukopenia during CDK4/6 inhibitor therapy was associated with improved OS. These data confirm that the degree of myelosuppression can serve as a valuable and readily available predictive biomarker of treatment effectiveness.
- Open Access
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 18-28
What we know about the new coronavirus infection in cancer patients
The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 18-28
Open AccessWhat we know about the new coronavirus infection in cancer patients
The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (4)
Cost of supportive cancer care in the Russian Federation. Part 2
Objective. To assess the cost of supportive drug therapy for 10 complications of malignant neoplasms according to the recommendations of the Russian Public Organization «Russian Society of Clinical Oncology» (RUSSCO). Material and methods. Considering the RUSSCO recommendations, we estimated drug therapy regimens for the following complications: anemia, hepatotoxicity, dermatological reactions, cardiovascular toxicity, neurological complications, nephrotoxicity, effects of extravasation, febrile neutropenia, nausea and vomiting, central venous access. To estimate the population requiring supportive therapy, we used data from registers of medical care bills for 2022. These reports contain information on the number of completed cases of antitumor drug therapy and the number of patients who received treatment. Literature data on the incidence of the above-mentioned complications were also used. Results. The largest financial costs (63.8% of all complications) were observed for the treatment of anemia (4 721 896 721.06 rubbles), hepatotoxicity (3 545 843 422.82 rubbles) and consequences of extravasation (2 388 137 692.57 rubbles). The oncology profile accounts for 66% of the estimated funding within this model. In the current model, 34% of the need is for preferential drug provision, 37% is additional need for compulsory medical insurance to finance the added cost of hospital-stay in a day hospital and 31% in a 24-hour hospital. Conclusion. These findings complement the previously published results for other complications presented in the RUSSCO recommendations. Calculation methodology and appropriate data can underlie further improvement of financing of supportive cancer therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (4)
Cost of supportive cancer care in the Russian Federation. Part 2
Objective. To assess the cost of supportive drug therapy for 10 complications of malignant neoplasms according to the recommendations of the Russian Public Organization «Russian Society of Clinical Oncology» (RUSSCO). Material and methods. Considering the RUSSCO recommendations, we estimated drug therapy regimens for the following complications: anemia, hepatotoxicity, dermatological reactions, cardiovascular toxicity, neurological complications, nephrotoxicity, effects of extravasation, febrile neutropenia, nausea and vomiting, central venous access. To estimate the population requiring supportive therapy, we used data from registers of medical care bills for 2022. These reports contain information on the number of completed cases of antitumor drug therapy and the number of patients who received treatment. Literature data on the incidence of the above-mentioned complications were also used. Results. The largest financial costs (63.8% of all complications) were observed for the treatment of anemia (4 721 896 721.06 rubbles), hepatotoxicity (3 545 843 422.82 rubbles) and consequences of extravasation (2 388 137 692.57 rubbles). The oncology profile accounts for 66% of the estimated funding within this model. In the current model, 34% of the need is for preferential drug provision, 37% is additional need for compulsory medical insurance to finance the added cost of hospital-stay in a day hospital and 31% in a 24-hour hospital. Conclusion. These findings complement the previously published results for other complications presented in the RUSSCO recommendations. Calculation methodology and appropriate data can underlie further improvement of financing of supportive cancer therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Cost of supportive cancer care in the Russian Federation. Part 1
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Cost of supportive cancer care in the Russian Federation. Part 1
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.
- 27 June 2023
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 12 (3)
Search for predictors of the efficiency of treatment with CDK4/6 inhibitors with HR+/HER2 metastatic breast cancer
АКТУАЛЬНОСТЬ Появившиеся в практике российского клинициста селективные ингибиторы CDK4/6 палбоциклиб и рибоциклиб изменили парадигму лечения больных с HR+HER2-РМЖ (РМЖ — рак молочной железы). Кандидатами для этой терапии могут стать в том числе больные, которым ранее рекомендовалась химиотерапия по поводу большой распространенности заболевания и пациентки с угрозой висцерального криза. Управляемый профиль безопасности является значимым аргументом в пользу выбора тактики применения ингибиторов CDK4/6. ЦЕЛЬ ИССЛЕДОВАНИЯ Выявление потенциальных предикторов эффективности терапии ингибиторами CDK4/6 в реальной клинической практике. МАТЕРИАЛ И МЕТОДЫ Ретроспективно исследована база данных, включающая 170 пациенток с метастатическим HR+ HER2- РМЖ, получавших лечение палбоциклибом и рибоциклибом в сочетании с эндокринотерапией в любой линии с 2019 по июнь 2020 г. в пяти онкологических диспансерах Сибири и Дальнего Востока. Исследовались влияние лейкопении и других факторов на продолжительность комбинированной эндокринотерапии, а также зависимость прогрессирования заболевания от выраженности нежелательных явлений. Конечной точкой была оценка длительности терапии ингибиторами CDK4/6 в зависимости от исследуемых факторов. Расчеты проводили с использованием критерия Колмогорова—Смирнова, коэффициента корреляции Спирмена, критерия Манна—Уитни, критерия χ2 Пирсона. Время до прогрессирования оценивали методом Каплана—Мейера. РЕЗУЛЬТАТЫ В группе пациенток с регистрируемой на фоне лечения палбоциклибом или рибоциклибом степенью лейкопении от менее 1 тыс. до 2,9 тыс. клеток на 1 мкл (кл/мкл) медиана времени до прогрессирования составила 35 мес по сравнению с группой пациенток, у которых не отмечалось лейкопении или фиксировался уровень лейкоцитов не менее 3 тыс. кл/мкл, медиана времени без прогрессирования составила 24 мес. ЗАКЛЮЧЕНИЕ Степень лейкопении от менее 1 тыс. до 2,9 тыс. кл/мкл потенциально может быть фактором большей продолжительности и маркером эффективности терапии ингибиторами CDK4/6 при лечении метастатического HR+HER2-РМЖ.
- 27 June 2023
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 12 (3)
Search for predictors of the efficiency of treatment with CDK4/6 inhibitors with HR+/HER2 metastatic breast cancer
АКТУАЛЬНОСТЬ Появившиеся в практике российского клинициста селективные ингибиторы CDK4/6 палбоциклиб и рибоциклиб изменили парадигму лечения больных с HR+HER2-РМЖ (РМЖ — рак молочной железы). Кандидатами для этой терапии могут стать в том числе больные, которым ранее рекомендовалась химиотерапия по поводу большой распространенности заболевания и пациентки с угрозой висцерального криза. Управляемый профиль безопасности является значимым аргументом в пользу выбора тактики применения ингибиторов CDK4/6. ЦЕЛЬ ИССЛЕДОВАНИЯ Выявление потенциальных предикторов эффективности терапии ингибиторами CDK4/6 в реальной клинической практике. МАТЕРИАЛ И МЕТОДЫ Ретроспективно исследована база данных, включающая 170 пациенток с метастатическим HR+ HER2- РМЖ, получавших лечение палбоциклибом и рибоциклибом в сочетании с эндокринотерапией в любой линии с 2019 по июнь 2020 г. в пяти онкологических диспансерах Сибири и Дальнего Востока. Исследовались влияние лейкопении и других факторов на продолжительность комбинированной эндокринотерапии, а также зависимость прогрессирования заболевания от выраженности нежелательных явлений. Конечной точкой была оценка длительности терапии ингибиторами CDK4/6 в зависимости от исследуемых факторов. Расчеты проводили с использованием критерия Колмогорова—Смирнова, коэффициента корреляции Спирмена, критерия Манна—Уитни, критерия χ2 Пирсона. Время до прогрессирования оценивали методом Каплана—Мейера. РЕЗУЛЬТАТЫ В группе пациенток с регистрируемой на фоне лечения палбоциклибом или рибоциклибом степенью лейкопении от менее 1 тыс. до 2,9 тыс. клеток на 1 мкл (кл/мкл) медиана времени до прогрессирования составила 35 мес по сравнению с группой пациенток, у которых не отмечалось лейкопении или фиксировался уровень лейкоцитов не менее 3 тыс. кл/мкл, медиана времени без прогрессирования составила 24 мес. ЗАКЛЮЧЕНИЕ Степень лейкопении от менее 1 тыс. до 2,9 тыс. кл/мкл потенциально может быть фактором большей продолжительности и маркером эффективности терапии ингибиторами CDK4/6 при лечении метастатического HR+HER2-РМЖ.
- Open Access
- 28 December 2020
- Published by Pacific State Medical University in Pacific Medical Journal
- No. 4,p. 5-9
Cancer patients having COVID-19 in Primorsky region: Morbidity and mortality
In the end of the year 2019 there was an outbreak of the new coronavirus infection with the epicenter in China, Wuhan (Hubei province). On 11th of February WHO defined an official name of the infection generated by new coronavirus – COVID-19 (COronaVIrus Disease 2019). On the 11th of February the International Committee on Virus Taxonomy assigned the name to the causative agent – SARS-CoV-2. The emergence of the COVID-19 set the task to the medical specialists connected with the fast diagnostics and providing medical treatment to the patients. Currently the intensive study of the clinical and epidemiological peculiarities of the disease, the development of new ways of prevention and treatment is the ongoing process. In this article the results of the morbidity and death rates connected with COVID-19 of the patients having cancer in Primorskiy region from 31st of March to 31st of August 2020 are introduced.
- 28 December 2020
- Published by Pacific State Medical University in Pacific Medical Journal
- No. 4,p. 5-9
Open AccessCancer patients having COVID-19 in Primorsky region: Morbidity and mortality
In the end of the year 2019 there was an outbreak of the new coronavirus infection with the epicenter in China, Wuhan (Hubei province). On 11th of February WHO defined an official name of the infection generated by new coronavirus – COVID-19 (COronaVIrus Disease 2019). On the 11th of February the International Committee on Virus Taxonomy assigned the name to the causative agent – SARS-CoV-2. The emergence of the COVID-19 set the task to the medical specialists connected with the fast diagnostics and providing medical treatment to the patients. Currently the intensive study of the clinical and epidemiological peculiarities of the disease, the development of new ways of prevention and treatment is the ongoing process. In this article the results of the morbidity and death rates connected with COVID-19 of the patients having cancer in Primorskiy region from 31st of March to 31st of August 2020 are introduced.